Archives
Please, enter cell line, author or any other phrase or word you would like to search for.
PHI terminates agreement regarding liquidity provider
PHI today announces that the Company has terminated the liquidity provider agreement with Pareto Securities AB. The agreement will expire on July 31, 2024.
HoloMonitor User Spotlight: Besa Xhabija
Dr. Besa Xhabija, Assistant Professor at the University of Michigan-Dearborn, shares how she integrates quantitative live cell imaging using HoloMonitor and AI tools in her cancer research.
BioStock: PHI “It’s the right moment to capitalize on regenerative medicine momentum.”
BioStock contacted CEO Patrik Eschricht for an update on the company’s progress and how PHI will capitalize on the current momentum.
PHI secures a loan facility of in total SEK 7 million
PHI announces that the Company has secured a loan facility of in total SEK 7 million from Bizcap AB, and from that loan facility decided to draw a tranche of SEK 4.5 million.
PHI announces conference schedule for spring 2024
PHI is pleased to announce a strategic activity schedule for spring 2024, during which PHI will participate in select industry webinars and events.
Interim Report 3 2023/24
This quarter set new records for PHI, achieving our highest-ever sales and advancing our strategic initiatives significantly. The strengthening of our partnership with Altium and the expanding reach of QPI technology highlights our leading position in the field. This quarter truly shows our continuous progress toward our core mission: making cell-based therapies accessible, affordable, and safe for all.
BioStock: Shift to regenerative medicine increases growth prospects for PHI
BioStock talked to our CEO, Patrik Eschricht, for an operational overview and to learn about the current behind-the-scenes developments, as PHI has a growth trajectory that is on a notable upward trend, marked by its highest-ever sales performances in the last quarter.
Bulletin from extraordinary general meeting in Phase Holographic Imaging PHI AB (publ) 14 March 2024
On Thursday, March 14, 2024, Phase Holographic Imaging PHI AB (publ), held an extraordinary general meeting. The following resolutions were passed at the meeting.
Shaping the future of Regenerative Medicine – PHI’s vision for QPI in Cell Therapy Manufacturing
PHI presents a comprehensive opinion piece detailing the versatility and potential the Company sees for Quantitative Phase Imaging (QPI) technology in Regenerative Medicine. PHI outlines how QPI will offer enhanced cell quality control in the cell manufacturing process, thereby addressing a central puzzle piece for making cell-based therapies safe, affordable, and accessible for all.
New Distributor Partner Manager at Altium set to enhance global sales for PHI
PHI is conveying the news that its global distributor, Altium ., has appointed a PHI-dedicated distributor partner manager. This strategic step is set to significantly enhance the reach and sales performance of PHI’s HoloMonitor technology on a global scale.